Drug Trial Radar · NCT00234832
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
Last checked: Nov 20, 2026Latest source record: May 11, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,777
Actual
Start
Jan 2003
Primary completion
Mar 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
Conditions
- Obesity
Interventions
Sibutramine hydrochlorideDrug
One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
PlaceboDrug
1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
Sibutramine hydrochlorideDrug
10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
Primary outcomes
What the sponsor says the trial is designed to measure.
- Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)Time frame: From randomization up to 6 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Medical Services
North Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.